Clinical Trial Update: IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 [Phase 2]

View source ↗

Summary

Phase 2 trial assessing intravenous immunoglobulin (IVIg) for small fiber neuropathy with autoantibodies TS-HDS and FGFR3 has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Peripheral Neuropathy
• Small Fiber Neuropathy

Drugs mentioned

• IVIG (intravenous immunoglobulin)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy | Phase 2 | Status: COMPLETED | Results posted: 2023-09-13